9-aminocamptothecin has been researched along with Carcinoma, Epidermoid in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lad, TE; Minami, H; Nicholas, MK; Ratain, MJ; Vokes, EE | 1 |
| Arietta, R; Brockstein, B; Keubler, JP; Lad, T; Rosen, F; Sciortino, D; Vokes, E | 1 |
| Burkey, B; Cmelak, A; Douglas, S; Murphy, BA; Netterville, J; Shyr, Y; Smith, W | 1 |
1 review(s) available for 9-aminocamptothecin and Carcinoma, Epidermoid
| Article | Year |
|---|---|
Topoisomerase I inhibitors in the treatment of head and neck cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Enzyme Inhibitors; Head and Neck Neoplasms; Humans; Irinotecan; Survival Analysis; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 2001 |
2 trial(s) available for 9-aminocamptothecin and Carcinoma, Epidermoid
| Article | Year |
|---|---|
Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.
Topics: Adult; Aged; Anticonvulsants; Blood Cell Count; Brain Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Glioma; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Logistic Models; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged | 1999 |
Phase II trial of aminocamptothecin (9-AC/DMA) in patients with advanced squamous cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged | 2000 |